Medicenna Therapeutics Corp. (MDNAF)
Develops immune-boosting drugs designed to activate the body's cancer-fighting cells
$0.25+0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-58.3%
The outlook
MDNAF is trading near its 52-week low at $0.25, well below both its 50- and 200-day moving averages, signaling a downtrend. Analyst coverage shows an average price target roughly 12x the current price, though sentiment leans bearish overall. The stock sits at the extreme bottom of its annual range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +1200% vs current price
Analyst price target
~12-month · 2 analysts$3.25average target+1200.0% vs now
Now $0.25
Low $2.50High $4.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$23.1M
52-wk high
$1.43
52-wk low
$0.23
50-day avg
$0.29
200-day avg
$0.60
Trailing P/E
—